Triple Negative Breast Cancer: From Mechanisms to Therapeutic Approaches
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".
Deadline for manuscript submissions: 30 June 2025 | Viewed by 45
Special Issue Editors
Interests: breast diagnostic pathology; breast molecular pathology; digital pathology and artificial intelligence (AI) in pathology
2. Department of Science, Rowland Hall, Salt Lake City, UT 84102, USA
Interests: triple-negative breast cancer; racial disparities in breast cancer outcomes; centrosome amplification and clustering; cell cycle regulation
Special Issue Information
Dear Colleagues,
It has been known for several years that the descriptor “Triple negative breast cancer (TNBC)” is a catch-all phrase for a constellation of distinct disease entities that share in common an absence of ER and PR expression and lack amplification of the HER2 gene. The prohibitive intra-tumoral and inter-tumor heterogeneity that typifies this group of breast tumors has also made the stratification of TNBC into biomarker-positive actionable subgroups a critical step that drives treatment decisions. Thus, deciphering the tumor biology and understanding the molecular vulnerabilities for various TNBC subgroups, right-sizing systemic therapies, and improving risk stratification (beyond residual disease burden and extent) are crucial, alongside advancements in drug discovery and development, for identifying optimal precision treatments, both in neoadjuvant and adjuvant settings.
For this Special Issue, we welcome original research papers and review articles focused on promising mechanism-informed therapies for TNBC, including, but not limited to, the following:
- HER2- and TROP2- based antibody-drug conjugates;
- Novel immune checkpoint inhibitors;
- Molecules targeting dsDNA repair pathways;
- Inhibitors of cell cycle regulators;
- Angiogenesis inhibitors;
- Agents that target microtubule dynamics;
- Agents that target centrosome clustering pathways;
- Notch pathway and FGFR inhibitors;
- EGFR inhibitors;
- PIK3K/AKT/mTOR inhibitors;
- Epigenetic modifiers;
- Monoclonal antibodies;
- Therapeutic vaccines;
- Endocrine therapies;
- Chemotherapies.
Dr. Emad Rakha
Dr. Padmashree Rida
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- triple-negative breast cancer
- neoadjuvant
- adjuvant
- chemotherapy
- immunotherapy
- antibody–drug conjugates
- immune checkpoint inhibitors
- DNA damage
- EGFR
- FGFR
- microtubule dynamics
- centrosome amplification
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
